Despite recent clinical advancements with anti-IL-6Rα antibodies in breast cancer, mAbs are large, lack BBB permeability, are expensive to develop, and, therefore, are not the best approach for our combination treatments. The gene discussed is IL6R; the disease is breast carcinoma.